Mexico Cell and Gene Therapy Market Size, Share, Trends and Forecast by Therapy Type, Indication, Delivery Mode, End User, and Region, 2026-2034
The Mexico cell and gene therapy market size reached USD 379.2 Million in 2025 . Looking forward, IMARC Group expects the market to reach USD 1,662.7 Million by 2034 , exhibiting a growth rate (CAGR) of 17.31 % during 2026-2034 . The market is driven by the rising prevalence of chronic disorders like cancer, diabetes, and orphan genetic diseases, unprecedented advances in biomedical research and development (R&D), and development of dedicated guidelines, and fast-track approval mechanisms for treatments targeting high-unmet medical needs or orphan diseases.
MEXICO CELL AND GENE THERAPY MARKET TRENDS:
Growing Prevalence of Chronic and Genetic Disorders
The rising prevalence of chronic disorders like cancer, diabetes, and orphan genetic diseases in Mexico is driving the need for innovative therapeutics, such as cell and gene therapies. These new treatments have the potential to cure or improve conditions that were previously considered incurable. For example, inherited diseases like hemophilia, sickle cell anemia, and lysosomal storage diseases are being addressed through gene therapies for correcting or substituting defective genes. Likewise, cell therapies using stem cells or Chimeric Antigen Receptor T-cell (CAR-T cells) are transforming oncology by expanding the immune system's capacity for recognizing and targeting tumor cells. This increasing disease burden is also fueling patient and healthcare professional interest in curative rather than lifelong management of symptoms. Consequently, the demand for novel biotechnological solutions and in-vitro diagnostics is accelerating, propelling the market growth. Furthermore, the IMARC Group predicts that the Mexico in-vitro diagnostics market size is expected to reach USD 3.5 Billion by 2033.
Advancements in Research and Local Biotech Infrastructure
Mexico is experiencing unprecedented advances in biomedical research and development (R&D), which are very important for developing and marketing cell and gene therapies. Universities like the National Autonomous University of Mexico (UNAM) and institutes like the National Institute of Genomic Medicine (INMEGEN) are all actively engaging in genetic studies, clinical trials, and translational medicine. These institutions not only promote innovation but also act as training centers for talented professionals in cell and molecular biology. In addition, the Mexican government and private investors are increasingly investing in the development of infrastructure, such as specialized laboratories, bioprocessing facilities, and clinical-grade manufacturing plants. These investments are critical to increase production scale and guarantee regulatory compliance for ATMPs. In 2024, President Claudia Sheinbaum unveiled the New Consolidated Procurement Model for Medicines and Medical Supplies for the 2025-2026 timeframe, which will require an investment of 130 billion pesos.
Regulatory Support and International Collaborations
Mexico's regulatory framework is getting updated to support the intricacies of cell and gene therapies. The Federal Commission for the Protection against Sanitary Risk (COFEPRIS) is actively working to streamline clinical trial approvals and commercialization of advanced treatments. This entails the development of dedicated guidelines and fast-track approval mechanisms for treatments targeting high-unmet medical needs or orphan diseases. These regulatory improvements have the purpose to balance innovation with patient safety so that the business climate becomes favorable for biopharmaceutical investment. In addition, Mexico is actively participating in global partnerships with North American and European biotechnology companies. Such alliances enable knowledge exchange, access to advanced technologies, and involvement in global clinical trials. The blend of regulatory flexibility and international integration greatly enhances the market's potential and its congruence with global standards. In 2025, Stem Vitality Mexico started accepting new patients who are looking for safe and effective stem cell therapy for various conditions. By providing treatments at a fraction of the price usually found in the United States and Canada, the clinic offers an affordable alternative for those dealing with chronic pain, autoimmune diseases, orthopedic conditions, and age-related problems. Foreign patients are assisted by Stem Vitality Mexico's medical tourism program, which features complimentary initial consultations, bilingual care coordinators, and complete travel assistance, providing a hassle-free experience from the San Diego border to the doors of the clinic.
MEXICO CELL AND GENE THERAPY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2026-2034. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.
Therapy Type Insights:
Indication Insights:
Delivery Mode Insights:
End User Insights:
Regional Insights:
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
MEXICO CELL AND GENE THERAPY MARKET TRENDS:
Growing Prevalence of Chronic and Genetic Disorders
The rising prevalence of chronic disorders like cancer, diabetes, and orphan genetic diseases in Mexico is driving the need for innovative therapeutics, such as cell and gene therapies. These new treatments have the potential to cure or improve conditions that were previously considered incurable. For example, inherited diseases like hemophilia, sickle cell anemia, and lysosomal storage diseases are being addressed through gene therapies for correcting or substituting defective genes. Likewise, cell therapies using stem cells or Chimeric Antigen Receptor T-cell (CAR-T cells) are transforming oncology by expanding the immune system's capacity for recognizing and targeting tumor cells. This increasing disease burden is also fueling patient and healthcare professional interest in curative rather than lifelong management of symptoms. Consequently, the demand for novel biotechnological solutions and in-vitro diagnostics is accelerating, propelling the market growth. Furthermore, the IMARC Group predicts that the Mexico in-vitro diagnostics market size is expected to reach USD 3.5 Billion by 2033.
Advancements in Research and Local Biotech Infrastructure
Mexico is experiencing unprecedented advances in biomedical research and development (R&D), which are very important for developing and marketing cell and gene therapies. Universities like the National Autonomous University of Mexico (UNAM) and institutes like the National Institute of Genomic Medicine (INMEGEN) are all actively engaging in genetic studies, clinical trials, and translational medicine. These institutions not only promote innovation but also act as training centers for talented professionals in cell and molecular biology. In addition, the Mexican government and private investors are increasingly investing in the development of infrastructure, such as specialized laboratories, bioprocessing facilities, and clinical-grade manufacturing plants. These investments are critical to increase production scale and guarantee regulatory compliance for ATMPs. In 2024, President Claudia Sheinbaum unveiled the New Consolidated Procurement Model for Medicines and Medical Supplies for the 2025-2026 timeframe, which will require an investment of 130 billion pesos.
Regulatory Support and International Collaborations
Mexico's regulatory framework is getting updated to support the intricacies of cell and gene therapies. The Federal Commission for the Protection against Sanitary Risk (COFEPRIS) is actively working to streamline clinical trial approvals and commercialization of advanced treatments. This entails the development of dedicated guidelines and fast-track approval mechanisms for treatments targeting high-unmet medical needs or orphan diseases. These regulatory improvements have the purpose to balance innovation with patient safety so that the business climate becomes favorable for biopharmaceutical investment. In addition, Mexico is actively participating in global partnerships with North American and European biotechnology companies. Such alliances enable knowledge exchange, access to advanced technologies, and involvement in global clinical trials. The blend of regulatory flexibility and international integration greatly enhances the market's potential and its congruence with global standards. In 2025, Stem Vitality Mexico started accepting new patients who are looking for safe and effective stem cell therapy for various conditions. By providing treatments at a fraction of the price usually found in the United States and Canada, the clinic offers an affordable alternative for those dealing with chronic pain, autoimmune diseases, orthopedic conditions, and age-related problems. Foreign patients are assisted by Stem Vitality Mexico's medical tourism program, which features complimentary initial consultations, bilingual care coordinators, and complete travel assistance, providing a hassle-free experience from the San Diego border to the doors of the clinic.
MEXICO CELL AND GENE THERAPY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the region level for 2026-2034. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.
Therapy Type Insights:
- Cell Therapy
- Stem Cell Pluripotent Stem Cell Cancer Stem Cell Adult Stem Cell
- Non-Stem Cell T-Cell Natural Killer Cell Others
- Gene Therapy
- Stem Cell
- Pluripotent Stem Cell
- Cancer Stem Cell
- Adult Stem Cell
- Non-Stem Cell
- T-Cell
- Natural Killer Cell
- Others
Indication Insights:
- Cardiovascular Disease
- Oncology Disorder
- Genetic Disorder
- Infectious Disease
- Neurological Disorder
Delivery Mode Insights:
- In-Vivo
- Ex-Vivo
End User Insights:
- Hospitals
- Cancer Care Centers
- Pharmaceutical and Biotechnology Companies
Regional Insights:
- Northern Mexico
- Central Mexico
- Southern Mexico
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the Mexico cell and gene therapy market performed so far and how will it perform in the coming years?
- What is the breakup of the Mexico cell and gene therapy market on the basis of therapy type?
- What is the breakup of the Mexico cell and gene therapy market on the basis of indication?
- What is the breakup of the Mexico cell and gene therapy market on the basis of delivery mode?
- What is the breakup of the Mexico cell and gene therapy market on the basis of end user?
- What is the breakup of the Mexico cell and gene therapy market on the basis of region?
- What are the various stages in the value chain of the Mexico cell and gene therapy market?
- What are the key driving factors and challenges in the Mexico cell and gene therapy market?
- What is the structure of the Mexico cell and gene therapy market and who are the key players?
- What is the degree of competition in the Mexico cell and gene therapy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MEXICO CELL AND GENE THERAPY MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 MEXICO CELL AND GENE THERAPY MARKET LANDSCAPE
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)
6 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY THERAPY TYPE
6.1 Cell Therapy
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2020-2025)
6.1.3 Market Segmentation
6.1.3.1 Stem Cell
6.1.3.1.1 Pluripotent Stem Cell
6.1.3.1.2 Cancer Stem Cell
6.1.3.1.3 Adult Stem Cell
6.1.3.2 Non-Stem Cell
6.1.3.2.1 T-Cell
6.1.3.2.2 Natural Killer Cell
6.1.3.2.3 Others
6.1.4 Market Forecast (2026-2034)
6.2 Gene Therapy
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2020-2025)
6.2.3 Market Forecast (2026-2034)
7 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY INDICATION
7.1 Cardiovascular Disease
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2020-2025)
7.1.3 Market Forecast (2026-2034)
7.2 Oncology Disorder
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2020-2025)
7.2.3 Market Forecast (2026-2034)
7.3 Genetic Disorder
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2020-2025)
7.3.3 Market Forecast (2026-2034)
7.4 Infectious Disease
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2020-2025)
7.4.3 Market Forecast (2026-2034)
7.5 Neurological Disorder
7.5.1 Overview
7.5.2 Historical and Current Market Trends (2020-2025)
7.5.3 Market Forecast (2026-2034)
7.6 Others
7.6.1 Historical and Current Market Trends (2020-2025)
7.6.2 Market Forecast (2026-2034)
8 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY DELIVERY MODE
8.1 In-Vivo
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2020-2025)
8.1.3 Market Forecast (2026-2034)
8.2 Ex-Vivo
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2020-2025)
8.2.3 Market Forecast (2026-2034)
9 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY END USER
9.1 Hospitals
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2020-2025)
9.1.3 Market Forecast (2026-2034)
9.2 Cancer Care Centers
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2020-2025)
9.2.3 Market Forecast (2026-2034)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2020-2025)
9.3.3 Market Forecast (2026-2034)
9.4 Others
9.4.1 Historical and Current Market Trends (2020-2025)
9.4.2 Market Forecast (2026-2034)
10 MEXICO CELL AND GENE THERAPY MARKET – BREAKUP BY REGION
10.1 Northern Mexico
10.1.1 Overview
10.1.2 Historical and Current Market Trends (2020-2025)
10.1.3 Market Breakup by Therapy Type
10.1.4 Market Breakup by Indication
10.1.5 Market Breakup by Delivery Mode
10.1.6 Market Breakup by End User
10.1.7 Key Players
10.1.8 Market Forecast (2026-2034)
10.2 Central Mexico
10.2.1 Overview
10.2.2 Historical and Current Market Trends (2020-2025)
10.2.3 Market Breakup by Therapy Type
10.2.4 Market Breakup by Indication
10.2.5 Market Breakup by Delivery Mode
10.2.6 Market Breakup by End User
10.2.7 Key Players
10.2.8 Market Forecast (2026-2034)
10.3 Southern Mexico
10.3.1 Overview
10.3.2 Historical and Current Market Trends (2020-2025)
10.3.3 Market Breakup by Therapy Type
10.3.4 Market Breakup by Indication
10.3.5 Market Breakup by Delivery Mode
10.3.6 Market Breakup by End User
10.3.7 Key Players
10.3.8 Market Forecast (2026-2034)
10.4 Others
10.4.1 Historical and Current Market Trends (2020-2025)
10.4.2 Market Forecast (2026-2034)
11 MEXICO CELL AND GENE THERAPY MARKET – COMPETITIVE LANDSCAPE
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant
12 PROFILES OF KEY PLAYERS
12.1 Company A
12.1.1 Business Overview
12.1.2 Services Offered
12.1.3 Business Strategies
12.1.4 SWOT Analysis
12.1.5 Major News and Events
12.2 Company B
12.2.1 Business Overview
12.2.2 Services Offered
12.2.3 Business Strategies
12.2.4 SWOT Analysis
12.2.5 Major News and Events
12.3 Company C
12.3.1 Business Overview
12.3.2 Services Offered
12.3.3 Business Strategies
12.3.4 SWOT Analysis
12.3.5 Major News and Events
12.4 Company D
12.4.1 Business Overview
12.4.2 Services Offered
12.4.3 Business Strategies
12.4.4 SWOT Analysis
12.4.5 Major News and Events
12.5 Company E
12.5.1 Business Overview
12.5.2 Services Offered
12.5.3 Business Strategies
12.5.4 SWOT Analysis
12.5.5 Major News and Events
13 MEXICO CELL AND GENE THERAPY MARKET - INDUSTRY ANALYSIS
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis
14 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MEXICO CELL AND GENE THERAPY MARKET - INTRODUCTION
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence
5 MEXICO CELL AND GENE THERAPY MARKET LANDSCAPE
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)
6 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY THERAPY TYPE
6.1 Cell Therapy
6.1.1 Overview
6.1.2 Historical and Current Market Trends (2020-2025)
6.1.3 Market Segmentation
6.1.3.1 Stem Cell
6.1.3.1.1 Pluripotent Stem Cell
6.1.3.1.2 Cancer Stem Cell
6.1.3.1.3 Adult Stem Cell
6.1.3.2 Non-Stem Cell
6.1.3.2.1 T-Cell
6.1.3.2.2 Natural Killer Cell
6.1.3.2.3 Others
6.1.4 Market Forecast (2026-2034)
6.2 Gene Therapy
6.2.1 Overview
6.2.2 Historical and Current Market Trends (2020-2025)
6.2.3 Market Forecast (2026-2034)
7 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY INDICATION
7.1 Cardiovascular Disease
7.1.1 Overview
7.1.2 Historical and Current Market Trends (2020-2025)
7.1.3 Market Forecast (2026-2034)
7.2 Oncology Disorder
7.2.1 Overview
7.2.2 Historical and Current Market Trends (2020-2025)
7.2.3 Market Forecast (2026-2034)
7.3 Genetic Disorder
7.3.1 Overview
7.3.2 Historical and Current Market Trends (2020-2025)
7.3.3 Market Forecast (2026-2034)
7.4 Infectious Disease
7.4.1 Overview
7.4.2 Historical and Current Market Trends (2020-2025)
7.4.3 Market Forecast (2026-2034)
7.5 Neurological Disorder
7.5.1 Overview
7.5.2 Historical and Current Market Trends (2020-2025)
7.5.3 Market Forecast (2026-2034)
7.6 Others
7.6.1 Historical and Current Market Trends (2020-2025)
7.6.2 Market Forecast (2026-2034)
8 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY DELIVERY MODE
8.1 In-Vivo
8.1.1 Overview
8.1.2 Historical and Current Market Trends (2020-2025)
8.1.3 Market Forecast (2026-2034)
8.2 Ex-Vivo
8.2.1 Overview
8.2.2 Historical and Current Market Trends (2020-2025)
8.2.3 Market Forecast (2026-2034)
9 MEXICO CELL AND GENE THERAPY MARKET - BREAKUP BY END USER
9.1 Hospitals
9.1.1 Overview
9.1.2 Historical and Current Market Trends (2020-2025)
9.1.3 Market Forecast (2026-2034)
9.2 Cancer Care Centers
9.2.1 Overview
9.2.2 Historical and Current Market Trends (2020-2025)
9.2.3 Market Forecast (2026-2034)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Historical and Current Market Trends (2020-2025)
9.3.3 Market Forecast (2026-2034)
9.4 Others
9.4.1 Historical and Current Market Trends (2020-2025)
9.4.2 Market Forecast (2026-2034)
10 MEXICO CELL AND GENE THERAPY MARKET – BREAKUP BY REGION
10.1 Northern Mexico
10.1.1 Overview
10.1.2 Historical and Current Market Trends (2020-2025)
10.1.3 Market Breakup by Therapy Type
10.1.4 Market Breakup by Indication
10.1.5 Market Breakup by Delivery Mode
10.1.6 Market Breakup by End User
10.1.7 Key Players
10.1.8 Market Forecast (2026-2034)
10.2 Central Mexico
10.2.1 Overview
10.2.2 Historical and Current Market Trends (2020-2025)
10.2.3 Market Breakup by Therapy Type
10.2.4 Market Breakup by Indication
10.2.5 Market Breakup by Delivery Mode
10.2.6 Market Breakup by End User
10.2.7 Key Players
10.2.8 Market Forecast (2026-2034)
10.3 Southern Mexico
10.3.1 Overview
10.3.2 Historical and Current Market Trends (2020-2025)
10.3.3 Market Breakup by Therapy Type
10.3.4 Market Breakup by Indication
10.3.5 Market Breakup by Delivery Mode
10.3.6 Market Breakup by End User
10.3.7 Key Players
10.3.8 Market Forecast (2026-2034)
10.4 Others
10.4.1 Historical and Current Market Trends (2020-2025)
10.4.2 Market Forecast (2026-2034)
11 MEXICO CELL AND GENE THERAPY MARKET – COMPETITIVE LANDSCAPE
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant
12 PROFILES OF KEY PLAYERS
12.1 Company A
12.1.1 Business Overview
12.1.2 Services Offered
12.1.3 Business Strategies
12.1.4 SWOT Analysis
12.1.5 Major News and Events
12.2 Company B
12.2.1 Business Overview
12.2.2 Services Offered
12.2.3 Business Strategies
12.2.4 SWOT Analysis
12.2.5 Major News and Events
12.3 Company C
12.3.1 Business Overview
12.3.2 Services Offered
12.3.3 Business Strategies
12.3.4 SWOT Analysis
12.3.5 Major News and Events
12.4 Company D
12.4.1 Business Overview
12.4.2 Services Offered
12.4.3 Business Strategies
12.4.4 SWOT Analysis
12.4.5 Major News and Events
12.5 Company E
12.5.1 Business Overview
12.5.2 Services Offered
12.5.3 Business Strategies
12.5.4 SWOT Analysis
12.5.5 Major News and Events
13 MEXICO CELL AND GENE THERAPY MARKET - INDUSTRY ANALYSIS
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis
14 APPENDIX
